DNA graphic

Funding

The Lupus Research Alliance seeks to fund biomedical research that will discover better diagnostics, improve medical treatments and advance translational and clinical research that will ultimately lead to a cure for lupus. The three grant mechanisms of the organization, Distinguished Innovator Award, Target Identification in Lupus and Novel Research Grant, provide distinct opportunities for researchers to test their most innovative hypothesis by applying cutting edge methodologies to further investigation in the lupus and autoimmune space.

Strategic Research Agreement provides up to $750,000 for up to three years. Pilot & Feasibility projects provide $200,000 for up to two years.

Lupus Research Alliance in partnership with JDRF and the National Multiple Sclerosis Society, is soliciting Letters of Intent (LOI) from investigators across autoimmune (and other relevant) fields to advance the understanding of autoimmunity and to obtain more specific insights into commonalities and differences of immune pathways that govern these pathogenic processes.

The incomplete knowledge of immune networks, pathways, disease pathogenesis and heterogeneity across multiple autoimmune diseases remains a challenge towards achieving optimal therapies to effectively treat all subjects in a given indication. The purpose of this call is to invite innovative ideas that address needs across multiple autoimmune diseases in novel ways that may allow us to make faster progress together.

Applications must address one or more of the following autoimmune/immune-mediated diseases: Type 1 Diabetes (T1D), Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS).

In response to this announcement, LOIs can be submitted under one of the following two mechanisms: (1) Strategic Research Agreement (SRA): proposed project budgets should not exceed $750,000 USD (including 10% indirect costs) total costs for up to three years. (2) Pilot & Feasibility (PNF): Pilot & Feasibility projects, with potential to evolve to larger efforts, are encouraged, and should be limited to a total proposed project budget of $200,000 USD (including 10% indirect costs) total costs for up to two years.

Click here for RFA.

Please send any scientific inquiries to Simi Ahmed from JDRF (sahmed@jdrf.org); all administrative inquiries should be sent to Jami Goodman, Project Manager, International Partnerships at jgoodman@jdrf.org. All other queries should be directed to Diomaris Gonzalez, Director of Grant Programs, at dgonzalez@lupusresearch.org.

The Distinguished Innovator Award grant mechanism is intended to attract exceptionally creative scientists from all relevant scientific disciplines and to provide them with a robust and sustained support to explore bold and paradigm shifting ideas that could lead to ground-breaking discoveries in lupus research.  Research conducted under this grant mechanism is expected to be highly innovative and to address the fundamental causes of systemic lupus erythematosus that can provide new directions towards a cure.

Click here for the Request for Applications. Please send any scientific inquiries to Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Cindy Liriano, Research Department Assistant at cliriano@lupusresearch.org.

To submit an Application, please visit proposalCentral at http://proposalcentral.altum.com/ and search for the Lupus Research Alliance Grant Application. All Letters of Intent must be received by 11:59 PM ET on Thursday, March 28, 2019.

Target Identification in Lupus (TIL): up to $200,000/year total costs for up to 3 years.

Supports highly meritorious research focused on the identification and scientific and/or clinical investigation of molecular pathways and therapeutic targets that will lead to new therapies or improved management for patients with lupus.

Please send any scientific inquiries to Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Diomaris Gonzales, Director, Grant Programs at dgonzalez@lupusresearch.org.

Please note that while the Target Identification in Lupus and the Novel Research Grants funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. The same research project may not be submitted for consideration to both grant mechanisms.  Such submissions will be triaged without review.

Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Novel Research Grants (NRG): up to $100,000/year total costs for up to 2 years.

They provide early stage support for highly innovative approaches to major challenges in lupus research. Special emphasis is placed on lupus studies exploring fundamental mechanisms, novel targets and pathways, novel technologies, and interdisciplinary approaches. Early-career investigators are encouraged to apply through this mechanism.

Please send any scientific inquiries to Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Diomaris Gonzales, Director, Grant Programs at dgonzalez@lupusresearch.org.

Please note that while the Novel Research Grants and the Target Identification in Lupus funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. The same research project may not be submitted for consideration to both grant mechanisms.  Such submissions will be triaged without review.

Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

The purpose of the LuCIN Investigator Initiated Clinical Trial (IICT) grant is to provide support to one or more well justified investigator initiated clinical trial (not fully funded by industry or other sources). It is designed to determine whether, and to what extent, promising new therapies can improve the lives of lupus patients. A primary focus is the evaluation of drugs that are currently approved for other indications and are available for use, known as drug repurposing, which has been a major focus of the Lupus Research Alliance’s interest in drug development for lupus. The intention of this program is to eliminate the barriers that typically hinder lupus clinical trials, ensuring that scientifically-sound treatment approaches are tested in lupus patients as quickly as possible.

Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Please email us at lupustherapeutics@lupusresearch.org if you would like additional information or have any questions about this grant.

Learn and connect with our community!